J. Martin Carroll remains with Company in Corporate Strategy and Development role.
Ridgefield, CT, January 23, 2012 – Paul R. Fonteyne has been named U.S. Country Managing Director and President and CEO of Boehringer Ingelheim USA Corporation effective January 1, 2012. Mr. Fonteyne assumes this role from J. Martin Carroll who remains with the Company in a Corporate Strategy and Development role, as well as a member of the Board of Boehringer Ingelheim USA Corporation.
Mr. Fonteyne was previously Corporate Senior Vice President, responsible for leading the global marketing strategy supporting Boehringer Ingelheim's Prescription Medicines business. In this role he successfully helped drive growth in the Company's core areas of respiratory and cardiovascular disease, as well as positioned it to successfully enter new areas of diabetes and oncology.
"Change is a necessary and healthy part of any successful company," said Mr. Carroll. "After nine years as President and CEO, it was time to let others take the lead on the day-to-day management of the company’s U.S. operations. I have worked with Paul for more than 15 years, and am confident that his depth and breadth of experience, combined with his passion for finding new ways to bring medicines to patients makes him well-suited to take on this role and help lead the Company to even greater success. I greatly appreciate the many contributions and efforts of everyone in the U.S. and globally that have helped grow this company during my tenure as U.S. leader."
"I am excited to be given the opportunity to lead the U.S. operations," said Mr. Fonteyne. "I believe this company is stronger now than at any point in its 126 year history. I look forward to working with my colleagues in the U.S. and globally to bring the best ideas to bear so that we may continue delivering on our commitment to bring more health to patients and their families."
About Boehringer Ingelheim
The Boehringer Ingelheim group of companies is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 42,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
As a central element of its culture, Boehringer Ingelheim pledges to act socially responsible. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors.
In 2010, Boehringer Ingelheim posted net sales of 12.6 billion euro while spending almost 24% of net sales in its largest business segment Prescription Medicines on research and development.